AMPE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 15:19):

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States...

Stats
Today's Volume	15 034.00
Average Volume	68 880.00
Market Cap	201 349
EPS	$0 ( 2024-03-25 )
Next earnings date	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.0230 (9.50%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-09	Buchi J Kevin	Buy	21 858	Common Stock
2023-06-08	Buchi J Kevin	Buy	25 000	Common Stock
2023-05-24	Martino Michael A	Buy	76 890	Common Stock
2023-05-16	Buchi J Kevin	Buy	32 534	Common Stock
2023-05-15	Buchi J Kevin	Buy	44 026	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 6 813 241 \| Sell: 1 519 396

Ampio Pharmaceuticals Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ampio Pharmaceuticals Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-10.66

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.530

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.820

Q1	2023
Revenue:	$0
Gross Profit:	$-245 000 (0.00 %)
EPS:	$-4.87

Financial Reports:

No articles found.

Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.